Literature DB >> 27690692

FGF21-FGFR1 Coordinates Phospholipid Homeostasis, Lipid Droplet Function, and ER Stress in Obesity.

Min Ye1, Weiqin Lu1, Xiaojie Wang1, Cong Wang1, James L Abbruzzese1, Guang Liang1, Xiaokun Li1, Yongde Luo1.   

Abstract

The antiobese and antidiabetic fibroblast growth factor 21 (FGF21) regulates lipid metabolism and energy homeostasis by targeting the βKlotho-FGFR1 (fibroblast growth factor receptor 1) binary complex in adipose tissue adipocytes. Because lipid droplet is the organelle responsible for storing lipid energy in adipocytes, it is the plausible target of FGF21 action. However, the impact of the FGF21-βKlotho-FGFR1 signaling pathway on the functions of the lipid droplet is not clearly understood. Using our mouse models of adipocyte-specific FGFR1 ablation and hepatic overexpression of FGF21 with diet-induced obesity established previously, we analyzed the alterations of the pathways involved in energy and substrate metabolism that is attributable to the dynamic functions of the lipid droplet. In addition to the previous reports showing that FGFR1 deficiency abrogated lipolysis, fatty acid oxidation, and energy expenditure promoted by the elevated FGF21 signal, we observed that the deficiency up-regulated the biosynthesis and remodeling of membrane phospholipids that are important for the biogenesis and expansion of the droplet, whereas the enhanced FGF21 signal constrained the biosynthesis of phospholipids. As a result, the loss of adipose FGFR1 led to a sustained droplet expansion and endoplasmic reticulum (ER) stress, whereas the enhanced FGF21 signal suppressed them in obesogenesis. These new findings reveal that the FGF21-βKlotho-FGFR1 signaling axis plays roles in maintaining phospholipid homeostasis and the dynamic functions of the lipid droplet, whereas protecting against ER stress, and suggest a potential link of phospholipid biosynthesis, lipid droplet dynamics, ER stress, and energy homeostasis in adipose tissue coordinated by this signaling axis.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27690692     DOI: 10.1210/en.2016-1710

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  18 in total

Review 1.  A review of fibroblast growth factor 21 in diabetic cardiomyopathy.

Authors:  Xiang Zhang; Luo Yang; Xiongfeng Xu; Fengjuan Tang; Peng Yi; Bo Qiu; Yarong Hao
Journal:  Heart Fail Rev       Date:  2019-11       Impact factor: 4.214

2.  The differential activation of metabolic pathways in leukemic cells depending on their genotype and micro-environmental stress.

Authors:  Caroline Lo Presti; Florence Fauvelle; Julie Mondet; Pascal Mossuz
Journal:  Metabolomics       Date:  2020-01-10       Impact factor: 4.290

3.  The fibroblast growth factor receptor antagonist SSR128129E inhibits fat accumulation via suppressing adipogenesis in mice.

Authors:  Xinzhi Zhang; Xin Wen; Geng Hu; Qiang Zhang; Qianying Sun; Yanxin Jia; Yan Liu; Hai Lin; Haifang Li
Journal:  Mol Biol Rep       Date:  2022-06-22       Impact factor: 2.742

4.  Increased FGF21 in brown adipose tissue of tyrosine hydroxylase heterozygous mice: implications for cold adaptation.

Authors:  Patricia Vázquez; Catalina Hernández-Sánchez; Carmen Escalona-Garrido; Laura Pereira; Cristina Contreras; Miguel López; Jesús Balsinde; Flora de Pablo; Ángela M Valverde
Journal:  J Lipid Res       Date:  2018-10-23       Impact factor: 5.922

Review 5.  FGF21 in obesity and cancer: New insights.

Authors:  Weiqin Lu; Xiaokun Li; Yongde Luo
Journal:  Cancer Lett       Date:  2020-11-29       Impact factor: 8.679

Review 6.  Identification and characterization of adipose surface epitopes.

Authors:  Yasuhiro Onogi; Ahmed Elagamy Mohamed Mahmoud Khalil; Siegfried Ussar
Journal:  Biochem J       Date:  2020-07-17       Impact factor: 3.857

Review 7.  Dyslipidemia in retinal metabolic disorders.

Authors:  Zhongjie Fu; Chuck T Chen; Gael Cagnone; Emilie Heckel; Ye Sun; Bertan Cakir; Yohei Tomita; Shuo Huang; Qian Li; William Britton; Steve S Cho; Timothy S Kern; Ann Hellström; Jean-Sébastien Joyal; Lois Eh Smith
Journal:  EMBO Mol Med       Date:  2019-09-05       Impact factor: 14.260

8.  Erythropoietin suppresses hepatic steatosis and obesity by inhibiting endoplasmic reticulum stress and upregulating fibroblast growth factor 21.

Authors:  Ting Hong; Zhijuan Ge; Bingjie Zhang; Ran Meng; Dalong Zhu; Yan Bi
Journal:  Int J Mol Med       Date:  2019-05-28       Impact factor: 4.101

9.  Fibroblast Growth Factor 21 Promotes C2C12 Cells Myogenic Differentiation by Enhancing Cell Cycle Exit.

Authors:  Xinyi Liu; Yongliang Wang; Shuhong Zhao; Xinyun Li
Journal:  Biomed Res Int       Date:  2017-10-04       Impact factor: 3.411

10.  Fibroblast Growth Factor 21 Attenuates Vascular Calcification by Alleviating Endoplasmic Reticulum Stress Mediated Apoptosis in Rats.

Authors:  Yuchen Shi; Shaoping Wang; Hongyu Peng; Yuan Lv; Wenzheng Li; Shujuan Cheng; Jinghua Liu
Journal:  Int J Biol Sci       Date:  2019-01-06       Impact factor: 6.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.